Amoxicillin/clavulanic acid extra strength - GlaxoSmithKline

Drug Profile

Amoxicillin/clavulanic acid extra strength - GlaxoSmithKline

Alternative Names: Augmentin ES; Augmentin ES Chewable; Augmentin ES-600; Dry syrup formulation of Augmentin ES; Extra strength amoxicillin/clavulanate potassium - GSK; Extra-strength amoxicillin/clavulanic acid

Latest Information Update: 03 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Beta-lactams; Penicillins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media
  • Discontinued Rhinosinusitis

Most Recent Events

  • 03 Feb 2016 Discontinued - Phase-III for Rhinosinusitis (In adolescents, In children, In infants) in Japan (PO)
  • 01 Nov 2013 GlaxoSmithKline completes a phase III trial in Rhinosinusitis (in infants, children and adolescents) in Japan (NCT01934231)
  • 01 Aug 2013 Phase-III clinical trials in Rhinosinusitis (in infants, children and adolescents) in Japan (PO; powder for oral suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top